WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Graph Therapeutics brings total funding to over $10M to advance precision immunology

Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology.

Raccontata datech.eutechfundingnews.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
tech.euStai leggendo1 g fa

Graph Therapeutics brings total funding to over $10M to advance precision immunology

Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology.

originale
techfundingnews.com1 g fa

The team behind Exscientia's $60M Allcyte acquisition just raised $5M from Daphni to build their own drugs —…

The team behind Allcyte, acquired by Exscientia in a $60M deal, has raised $5M from Daphni to build its own drugs. The startup Graph is now moving from platform science to drug creation.

Leggi questa versione → originale

Timeline cronologica

  1. lunedì 22 giugno 2026·tech.eu

    Graph Therapeutics brings total funding to over $10M to advance precision immunology

    Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics…

  2. lunedì 22 giugno 2026·techfundingnews.com

    The team behind Exscientia's $60M Allcyte acquisition just raised $5M from Daphni to build their own drugs — TFN

    The team behind Allcyte, acquired by Exscientia in a $60M deal, has raised $5M from Daphni to build its own drugs. The startup Graph is now moving from platform science to drug…